Clinical trial
Open access
Eltrombopag during induction chemotherapy in older patients with newly diagnosed acute myeloid leukemia is safe and reduces platelet transfusion requirements: The EPAG‐2015 French Innovative Leukemia Organization phase 2 randomized trial
A. Pigneux
P. Dumas
Marc Bernard
Norbert Vey
A. Bidet
Ariane Mineur
Aline Schmidt
Martin Carré
M. Ojeda
S. Bertoli
A. Banos
P. Peterlin
R. Guièze
Y. Desbrosses
Gabrielle Roth Guepin
C. Simand
T. Leguay
E. Gyan
Eric Jourdan
J. Vial
Tony Marchand
Y. Hicheri
M. Béné
jean-François Hamel
Christian Récher
Medicine
Abstract
Elderly patients with acute myeloid leukemia (AML) treated with intensive chemotherapy are at risk of developing thrombopenia, which requires platelet transfusions. It would be interesting to provide them with thrombopoietin receptor agonists such as eltrombopag.